Method for detecting Salmonella infection using SsaK protein
The SsaK protein is used as an antigen to detect anti-Salmonella antibodies, addressing the challenge of differentiating infected from vaccinated individuals, thereby enhancing infection control in animals and humans.
Patent Information
- Application Number
- JP2021172591
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-10-21
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2041-10-21
AI Technical Summary
Current methods for detecting Salmonella infection in livestock and poultry are limited by the inability to distinguish between individuals infected with Salmonella and those vaccinated with an inactivated vaccine, leading to false positive results and difficulties in infection control.
Utilizing the SsaK protein, which is part of the type III secretion apparatus of Salmonella, as an antigen to immunologically detect anti-Salmonella antibodies, allowing differentiation between infected and vaccinated individuals.
The method enables accurate and simple detection of Salmonella infection, preventing its spread in animals and humans, and aiding in existing diagnostic methods by distinguishing between infected and vaccinated individuals.
Smart Images

Figure 0007595938000002 
Figure 0007595938000003 
Figure 0007595938000004
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for detecting infection with Salmonella genus bacteria using the SsaK protein, as well as an antigen reagent and a kit for use in said detection method. [Background technology]
[0002] Salmonella is a gram-negative bacillus that is subdivided into more than 2,600 serotypes. Salmonellosis (livestock and poultry) and poultry Salmonella infection are designated as notifiable and legally required infectious diseases under the Livestock Infectious Diseases Prevention Law, respectively, and it is important to take measures to prevent these infections. When livestock or poultry are infected with Salmonella, the main symptoms are fever, loss of appetite, and loss of energy, and it can cause acute septicemia and chronic diarrhea. However, due to the limitations of scientific methods, the occurrence of Salmonellosis in livestock and poultry both in Japan and overseas has not been completely suppressed. In addition, farms where Salmonellosis has occurred can have difficulty in purifying the bacteria.
[0003] As part of efforts to purify the bacteria, monitoring is being carried out by isolating and culturing the bacteria from hosts and measuring antibodies in serum. By periodically measuring antibodies in serum, it becomes possible to estimate the time of infection with Salmonella and take appropriate infection control measures.
[0004] On the other hand, if salmonellosis occurs on a farm, a vaccine may be administered to prevent the spread of infection. The Salmonella vaccine currently administered to cows and chickens in Japan is a vaccine in which the bacteria are inactivated by treatment with formalin, and is a very effective means of preventing infection.
[0005] However, when anti-Salmonella antibodies in the serum of vaccinated individuals are measured, they show a positive reaction, just like those in individuals infected with Salmonella. In other words, vaccination results in a scientific flaw in that it becomes impossible to distinguish between individuals infected with Salmonella and those not infected. For this reason, there is a need for a test method that can distinguish between individuals infected with Salmonella and those vaccinated.
[0006] Known examples of test methods that enable such discrimination include a test method that utilizes proteins that constitute flagellar antigens of bacteria of the genus Salmonella (Patent Document 1). [Prior art documents] [Patent documents]
[0007] [Patent Document 1] International Publication No. 2004 / 055045 Summary of the Invention [Problem to be solved by the invention]
[0008] The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a new method capable of detecting individuals infected with Salmonella spp. by distinguishing them from individuals vaccinated with an inactivated vaccine, and also to provide a reagent and a kit for use in said detection. [Means for solving the problem]
[0009] The present inventors conducted extensive research to solve the above problems, and found that the SsaK protein, which is one of the proteins constituting the type III secretion apparatus of Salmonella bacteria, has a higher affinity for anti-Salmonella antibodies produced by individuals infected with Salmonella bacteria than for anti-Salmonella antibodies produced by individuals vaccinated with an inactivated vaccine, and that infection with Salmonella bacteria can be detected with high accuracy by using the protein as an antigen for detecting anti-Salmonella antibodies. On the other hand, when proteins secreted outside the cells by the type III secretion apparatus of Salmonella bacteria (SseG protein and SseF protein), a cell membrane protein (LptD protein), and LPS (Lipopolysaccharide) were used as antigens, no significant difference was observed in the affinity for the two anti-Salmonella antibodies. From the above, it was found that the specificity shown by the SsaK protein is not a phenomenon common to the molecules constituting Salmonella bacteria.
[0010] Based on the above findings, the present invention relates to a method for detecting infection with Salmonella spp. using the SsaK protein, and a reagent and kit for use in said detection method, and more specifically provides the following:
[0011] (1) A method for detecting infection with Salmonella, comprising immunologically detecting anti-Salmonella antibodies in a sample using the SsaK protein or a functional fragment thereof as an antigen.
[0012] (2) An antigen reagent for immunologically detecting infection with Salmonella spp., comprising an SsaK protein or a functional fragment thereof.
[0013] (3) A kit for immunologically detecting infection with Salmonella spp., comprising the antigen reagent according to (2). Effect of the Invention
[0014] According to the present invention, it is possible to easily and accurately detect infection with Salmonella bacteria using SsaK protein. Salmonella bacteria are causative bacteria of zoonotic diseases that infect livestock and poultry, affecting their productivity and causing economic losses, as well as causing food poisoning in humans. By using the present invention, it is possible to efficiently prevent infection with Salmonella bacteria in animals such as livestock and poultry, and in humans. In particular, in chickens, the serum of vaccinated individuals may give a false positive response to a pullorum rapid agglutination diagnostic solution used to diagnose pullorum (poultry Salmonella infection), making it difficult to diagnose pullorum. The present invention can also be used as an adjunct to such existing diagnoses. [Brief description of the drawings]
[0015]
Figure 1A
Figure 1B
Figure 1C
Figure 1D
Figure 1E
[0016] The present invention provides a method for detecting infection with Salmonella spp., which comprises immunologically detecting anti-Salmonella antibodies in a sample using the SsaK protein or a functional fragment thereof as an antigen.
[0017] Examples of "Salmonella bacteria" to be detected for infection in the detection method of the present invention include, but are not limited to, Salmonella bacteria of each serotype, such as Salmonella Typhimurium, Salmonella Choleraesuis, Salmonella Dublin, Salmonella Enteritidis, Salmonella Gallinarum, and Salmonella Pullorum, which belong to Salmonella enterica subsp. enterica.
[0018] In the present invention, the "sample" used for detecting Salmonella infection is not particularly limited as long as it is a sample in which anti-Salmonella antibodies can be present. In general, it is a blood sample such as serum, plasma, and whole blood collected from an individual that can be infected with Salmonella. The organism from which the sample is derived is not particularly limited as long as it is an organism that can be infected with Salmonella, and includes humans and other animals. The animal may be a livestock animal, a pet animal, an experimental animal, or an animal for other purposes. Examples of the animal include, but are not limited to, chickens, ducks, geese, ducks, quails, pheasants, pigeons, turkeys, guinea fowl, cows, pigs, horses, sheep, goats, dogs, and cats.
[0019] These samples may be diluted or suspended in a diluent as necessary. Examples of the diluent include buffers such as phosphate buffer, Tris buffer, Good's buffer, borate buffer, acetate buffer, citrate buffer, glycine buffer, succinate buffer, and phthalate buffer. The samples of the present invention may be pretreated as necessary. Examples of pretreatment include freezing, concentration, fractionation, purification, and the like, and addition of pH adjusters, stabilizers, preservatives, and antiseptics, and the like. These treatments may be performed by one type or a combination of two or more types.
[0020] In the present invention, anti-Salmonella antibodies in a sample are detected as an indicator of Salmonella infection. An "anti-Salmonella antibody" is an antibody capable of specifically binding to the Salmonella bacteria, more specifically, an antibody produced in the body of an individual from which a sample is derived. The isotype of the anti-Salmonella antibody may vary depending on the species of organism, and may be, for example, any of IgY, IgG, IgM, and IgA, or a combination of two or more of these. In addition, the isotype may be any subclass. The appearance and duration of anti-Salmonella antibodies in an individual's body after infection with Salmonella bacteria may vary depending on the type of antibody. Therefore, the Salmonella infection detected in the present invention includes current and past infection with Salmonella bacteria.
[0021] The present invention is characterized in that the SsaK protein or a functional fragment thereof is used as an antigen for detecting anti-Salmonella antibodies. The "SsaK protein" is one of the proteins constituting the type III secretion system that secretes proteins outside the cells of Salmonella bacteria. A typical amino acid sequence of the SsaK protein is shown in SEQ ID NO: 2, and a typical base sequence of the DNA encoding the protein is shown in SEQ ID NO: 1. However, it should be understood that in nature, the amino acid sequence of the protein may change due to genetic mutation. A "functional fragment" of the SsaK protein may also be used as an antigen. Here, the functional fragment means a fragment of the SsaK protein that has binding activity to anti-Salmonella antibodies. The binding activity of the SsaK protein fragment to anti-Salmonella antibodies can be evaluated by the immunological method described below. The SsaK protein or its functional fragment may be modified, such as by introducing a mutation, as long as the binding activity to anti-Salmonella antibodies is not impaired.
[0022] The SsaK protein or a functional fragment thereof can be prepared as a recombinant protein or a natural protein by a method well known in the art. The recombinant protein can be prepared, for example, by inserting a DNA encoding the SsaK protein (e.g., a DNA containing the nucleotide sequence set forth in SEQ ID NO: 1) or a DNA encoding a fragment of the protein into an appropriate expression vector, introducing the vector into an appropriate host cell, and purifying the protein from an extract or culture supernatant of the host cell. Examples of purification methods include, but are not limited to, ion exchange chromatography, reverse phase chromatography, and gel filtration. In addition, when the SsaK protein or a fragment thereof is expressed in a host cell (e.g., E. coli, etc.) as a recombinant protein to which multiple histidines have been added, or as a fusion protein with a glutathione-S-transferase protein, the expressed recombinant protein can be affinity purified using a nickel column or a glutathione column, respectively. After purification of the fusion protein, regions other than the target protein or fragment can be removed by cleavage with thrombin or factor Xa as necessary. The native protein can be prepared by methods known to those skilled in the art, for example, by contacting an extract of Salmonella with an affinity column to which an antibody against the SsaK protein is bound.
[0023] The detection principle of the immunoassay used in the present invention is preferably the sandwich method, since it allows the construction of a highly sensitive detection system. In the sandwich method, anti-Salmonella antibodies are captured by a solid-phase capture molecule, which is then recognized by a detection molecule bound to a labeling substance, and after washing, detection is performed according to the type of labeling substance. For example, a plate such as a plastic plate, a fibrous material such as nitrocellulose, or particles such as magnetic particles or latex particles can be used as the solid phase.
[0024] In the sandwich method, the SsaK protein or a functional fragment thereof is used as an antigen for at least one of the molecules for capturing and detecting the anti-Salmonella antibody. The other molecule is not particularly limited as long as it can bind to the anti-Salmonella antibody, and may be, for example, an antibody against the anti-Salmonella antibody (secondary antibody) or another protein that binds to the anti-Salmonella antibody.
[0025] A labeling substance is usually bound to the detection molecule. There is no particular limitation on the labeling substance as long as it is a detectable substance, but examples of the labeling substance include enzymes such as horseradish peroxidase (HRP), alkaline phosphatase (ALP), and β-galactosidase (β-gal), fluorescent dyes such as fluorescein isothiocyanate (FITC) and rhodamine isothiocyanate (RITC), fluorescent proteins such as allophycocyanin (APC) and phycoerythrin (R-PE), 125 Examples of labeling substances include radioisotopes such as I, gold particles, avidin, biotin, latex, etc. When an enzyme is used as a labeling substance, various detection methods can be performed depending on the substrate by adding a chromogenic substrate, a fluorescent substrate, or a chemiluminescent substrate as a substrate.
[0026] When quantifying anti-Salmonella antibodies in a sample, a sandwich method using a microplate well or beads as the solid phase, such as ELISA, is preferred. The amount of anti-Salmonella antibodies from the measured values is generally determined by comparison with the measured values from a standard sample. In this case, the amount of anti-Salmonella antibodies in the sample can be determined, for example, by determining where the actual measured values are located on a standard curve created based on the measured values from the standard sample.
[0027] On the other hand, immunochromatography is suitable for detecting anti-Salmonella antibodies simply and quickly. One embodiment of an immunochromatographic device is described below. The device includes a detection zone in which a capture molecule is immobilized in a line on a matrix made of a porous material such as a nitrocellulose membrane, and a labeling reagent zone carrying a labeled detection molecule upstream of the detection zone. Usually, the labeling reagent zone is composed of a porous pad carrying the labeled detection molecule. A developer tank storing a developer is provided at the upstream end of the matrix. Furthermore, usually, downstream of the detection zone, a development confirmation section in which a molecule capturing the detection molecule is immobilized in a line to confirm the development of the labeled detection molecule, and downstream of that, a developer absorption zone in which a porous absorption pad for absorbing the developer is provided. Furthermore, when the label is an enzyme label, a substrate zone carrying a substrate for the labeling enzyme is provided upstream of the labeling reagent zone.
[0028] In use, a sample is added to the labeled reagent zone, and the developer pad is inserted into the developer tank by applying pressure to the pusher to move the protrusion, and the developer is supplied to the matrix through the developer pad. When the developer passes through the substrate zone, the substrate is dissolved in the developer, and the developer containing the substrate flows. When the developer passes through the labeled reagent zone, the labeled detection molecule and the sample are dissolved in the developer, and the developer containing the substrate, the labeled detection molecule, and the sample flows. When the sample contains an anti-Salmonella antibody, the anti-Salmonella antibody and the labeled detection molecule bind to form a complex, and when this complex reaches the detection zone, the capture molecule on the detection zone binds to the anti-Salmonella antibody in the complex. As a result, the labeled detection molecule is fixed to the detection zone via the anti-Salmonella antibody. The label in the detection zone is measured in this way to detect the anti-Salmonella antibody. If the sample does not contain anti-Salmonella antibodies, the labeled detection molecule will not be fixed to the detection zone and will move further downstream, and the label will not be detected in the detection zone. Note that the developer confirmation section downstream of the detection zone has a solid phase molecule that captures the detection molecule, so the labeled detection molecule will be fixed to the developer confirmation section. Therefore, when a label is detected in the developer confirmation section, it means that the developer has been developed correctly. The developer is finally absorbed by the absorbent pad downstream of that.
[0029] According to the detection method of the present invention, it is possible to distinguish between individuals infected with Salmonella bacteria and individuals vaccinated with inactivated Salmonella bacteria as a vaccine. Inactivated Salmonella bacteria to be used as a vaccine can be prepared, for example, by heat treatment of Salmonella bacteria, treatment with a chemical disinfectant, irradiation with radiation or ultraviolet light, treatment with a mutagenic substance, etc. As the inactivation treatment, heat treatment or treatment with formalin, which is a chemical disinfectant, is preferably used. The inactivated Salmonella bacteria may be a mixture of different Salmonella bacteria (e.g., a mixture of Salmonella bacteria of different species or different serotypes).
[0030] The present invention also provides an antigen reagent for immunologically detecting infection with Salmonella genus bacteria, comprising the SsaK protein or a functional fragment thereof. The antigen reagent may consist of only the SsaK protein or a functional fragment thereof, which is an antigen, or may be bound to a labeling substance or may be immobilized thereon. The antigen reagent may also be a composition comprising these. Other components contained in the composition are not particularly limited, and examples thereof include sterilized water, physiological saline, a surfactant, a preservative, and the like, and may be one type of these or a combination of two or more types thereof.
[0031] The present invention also provides a kit for immunologically detecting infection with Salmonella genus bacteria, comprising the antigen reagent. The kit may further comprise components to be included in immunological detection methods in addition to the antigen reagent. Such components include, but are not limited to, standard samples (such as anti-Salmonella antibodies at various concentrations), control reagents, reaction buffers, diluents, and washing solutions. When the labeling substance is an enzyme, the kit may further comprise a substrate or a reaction stop solution necessary for detection and quantification of the labeling substance.
[0032] When the sandwich method is employed for detection, and a solid phase to which the SsaK protein or a functional fragment thereof is bound is used as a molecule for capturing anti-Salmonella antibodies (one embodiment of the antigen reagent of the present invention), the kit of the present invention may further comprise a secondary antibody bound to a labeling substance as a molecule for detecting anti-Salmonella antibodies. On the other hand, when a labeled SsaK protein or a functional fragment thereof is used as a molecule for detecting anti-Salmonella antibodies (one embodiment of the antigen reagent of the present invention), the kit of the present invention may further comprise a solid phase to which a secondary antibody or the like is bound as a molecule for capturing anti-Salmonella antibodies.
[0033] In addition, when immunochromatography is employed for detection, the device may further include a zone carrying a capture molecule for anti-Salmonella antibodies and / or a labeled detection molecule. The device may include other components suitable for immunochromatography, such as a developer pad or an absorbent pad.
[0034] The kit of the present invention may further include instructions for use of the kit. EXAMPLES
[0035] The present invention will be described more specifically below based on examples and comparative examples.
[0036] A. Materials and Methods (1) Purification of antigen The Salmonella-derived molecules used as antigens are as follows:
[0037] (a) Example SsaK protein (226 amino acids, molecular weight 26162, part of the type III secretion apparatus that secretes Salmonella proteins outside the cell) (SEQ ID NO: 1, 2)
[0038] (b) Comparative example (i) SseG protein (230 amino acids, molecular weight 24237, protein secreted outside the bacterial cell by the type III secretion apparatus) (SEQ ID NOs: 3 and 4) (ii) SseF protein (261 amino acids, molecular weight 26595, protein secreted outside the bacterial cell by the type III secretion apparatus) (SEQ ID NOs: 5 and 6) (iii) LptD protein (786 amino acids, molecular weight 89540, bacterial membrane protein) (SEQ ID NOs: 7 and 8) (iv) Lipopolysaccharide (LPS)
[0039] (2) Cloning of antigen genes Salmonella enterica PCR was performed using the DNA of serovar Typhimurium x3306 strain as a template and various primers listed in Table 1.
[0040] [Table 1]
[0041] Next, the PCR products were cloned using the TOPO cloning method, and then each Salmonella protein described in (1) was highly expressed in E. coli. pET151 / D-TOPO was used as the plasmid for protein expression. A His tag (6x) was added to the N-terminus of the protein expressed using this plasmid.
[0042] (3) Purification of antigen The Salmonella bacteria were pre-cultured (static culture) overnight in 5 mL of LB medium (containing ampicillin). Then, they were shake-cultured in 100 mL of LB medium until the absorbance (600 nm) reached 0.3, and isopropyl-β-D-thiogalactopyranoside was added and cultured for another 6 hours. After the culture, the cells were collected and disrupted by ultrasonic treatment. The disrupted cells were then dissolved in urea lysis buffer, and various proteins were captured and purified using a nickel column, and eluted with imidazole elution buffer.
[0043] LPS was purified from Salmonella bacteria that had been statically cultured overnight at 37°C in 5 ml of LB medium using an LPS extraction kit (iNtRON).
[0044] (4) Chicken serum For chickens (white leghorn), at 1 week and 3 weeks of age, Salmonella enterica Serum was collected two weeks after two inoculations of serovar Typhimurium or inactivated vaccine (heat-inactivated killed bacteria).
[0045] In Salmonella spp.-infected groups, Salmonella enterica Serovar Typhimurium aroA Mutant strain (1x10 7The mice were inoculated intravenously twice with 100 μl of PBS (CFU / ml / 200 μl PBS).
[0046] In the vaccinated group, the virus was inactivated by heat treatment at 100°C for 5 minutes. Salmonella enterica Serovar Typhimurium aroA Mutant strain (1x10 7 The mice were inoculated intravenously twice with 100 μl of PBS (CFU / ml / 200 μl PBS).
[0047] (5) ELISA Antigen (recombinant Salmonella protein) adjusted to 0.5 μg / ml was reacted at 37°C for 1 hour to immobilize the antigen, and then blocked at room temperature for 1 hour using Blocking One (Nacalai Tesque). Next, serum from the Salmonella-infected group and the vaccinated group were reacted with the immobilized proteins at 37°C for 1 hour, and a secondary antibody (HRP-labeled rabbit anti-chicken IgY antibody) was reacted at 37°C for 1 hour. Next, TMB (3,3',5,5'-tetramethylbenzidine) was added as a substrate to develop the HRP label, and chicken IgY was quantified using an absorbance plate reader (450 nm).
[0048] B. Results (1) ELISA using recombinant SsaK protein as an antigen in chickens When chicken serum was subjected to ELISA using the SsaK protein, a type III secretion system protein, as an antigen, the serum antibody titer was higher in the Salmonella-infected group than in the vaccinated group (Fig. 1A). On the other hand, the SseG protein, SseF protein, the membrane protein LptD protein, and the SseG protein, which are secreted by the type III secretion system, were not detected. Salmonella enterica When LPS derived from serovar Typhimurium x3306 was used as an antigen, no significant difference was observed in serum antibody titers between the Salmonella -infected and vaccinated groups (Fig. 1B-E). These results demonstrated that the SsaK protein is an antigen that can distinguish between vaccinated and Salmonella -infected individuals. [Industrial Applicability]
[0049] According to the present invention, it is possible to identify individuals infected with Salmonella by distinguishing them from individuals vaccinated with an inactivated vaccine. The present invention is particularly applicable in the fields of agriculture and medicine. [Sequence List Free Text]
[0050] SEQ ID NO: 9 to 16 <223> Primer sequences
Claims
1. A method for detecting infection with Salmonella, comprising immunologically detecting anti-Salmonella antibodies in a sample using, as an antigen, an SsaK protein or a fragment of an SsaK protein having binding activity to an anti-Salmonella antibody.
2. An antigen reagent for immunologically detecting infection with Salmonella, comprising an SsaK protein or a fragment of an SsaK protein having binding activity for an anti-Salmonella antibody.
3. A kit for immunologically detecting Salmonella infection, comprising the antigen reagent of claim 2.
Citation Information
Patent Citations
Measuring method for antibody of salmonella germ
JP1999023576A
Salmonella antigen formulation and salmonella antibody detection kit
JP2002525605A
Salmonella antigen formulation and antibody test kit and subunit vaccine using the same
WO2004055045A1
